IgG antibody response against nucleocapsid and spike protein post-SARS-CoV-2 infection. 2021

Hari Ram Choudhary, and Debaprasad Parai, and Girish Chandra Dash, and Annalisha Peter, and Subrat Kumar Sahoo, and Matrujyoti Pattnaik, and Usha Kiran Rout, and Rashmi Ranjan Nanda, and Sanghamitra Pati, and Debdutta Bhattacharya
Department of Microbiology, ICMR-Regional Medical Research Centre (Department of Health Research, Ministry of Health and Family Welfare, Government of India), Chandrasekharpur, Bhubaneswar, 751023, India.

OBJECTIVE Coronavirus disease-19 (COVID-19) pandemic became the greatest public health challenge globally. Study of dynamicity and durability of naturally developed antibodies against SARS-CoV-2 are of great importance from an epidemiological viewpoint. METHODS In this observational cohort study, we have followed up the 76 individuals who tested positive for SARS-CoV-2 infection by real-time reverse transcriptase-polymerase chain reaction (RT-qPCR) for 16 weeks (post-enrolment) to record the periodic changes in titre, concentration, clinical growth and persistence of naturally developed SARS-CoV-2 antibodies. We collected serum samples from these individuals for 16 weeks with a frequency of weekly and fortnightly during each follow-up and tested them in two CLIA-based platforms (Abbott Architect i1000SR and Roche Cobas e411) for testing SARS-CoV-2 antibodies both qualitatively and quantitatively. RESULTS We recorded the antibody magnitude of these individuals 10 times between September 2020 and February 2021. We found a waning of antibodies against nucleocapsid antigen protein but not a complete disappearance by the end of 16 weeks. Out of 76 cases, 30 cases (39.47%) became seronegative in qualitative assay, although all the sera samples (100%) remained positive when tested in quantitative assay. CONCLUSIONS The lower persistence of anti-nucleocapsid SARS-CoV-2 antibody may not be the exact phenomenon as those cases were still seropositive against spike protein and help in neutralising the virus.

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D000917 Antibody Formation The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS. Antibody Production,Antibody Response,Antibody Responses,Formation, Antibody,Production, Antibody,Response, Antibody,Responses, Antibody
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity
D019251 Nucleocapsid A protein-nucleic acid complex which forms part or all of a virion. It consists of a CAPSID plus enclosed nucleic acid. Depending on the virus, the nucleocapsid may correspond to a naked core or be surrounded by a membranous envelope. Nucleocapsids
D064370 Spike Glycoprotein, Coronavirus A class I viral fusion protein that forms the characteristic spikes, or peplomers, found on the viral surface that mediate virus attachment, fusion, and entry into the host cell. During virus maturation, it is cleaved into two subunits: S1, which binds to receptors in the host cell, and S2, which mediates membrane fusion. Spike Glycoprotein, Bovine Coronavirus,Spike Glycoproteins, Coronavirus,E2 Spike Glycoprotein, Coronavirus,Glycoprotein S, Coronavirus,Spike Glycoprotein S1, Coronavirus,Spike Protein S2, Coronavirus,Spike Protein, Coronavirus,Coronavirus Spike Glycoprotein,Coronavirus Spike Protein

Related Publications

Hari Ram Choudhary, and Debaprasad Parai, and Girish Chandra Dash, and Annalisha Peter, and Subrat Kumar Sahoo, and Matrujyoti Pattnaik, and Usha Kiran Rout, and Rashmi Ranjan Nanda, and Sanghamitra Pati, and Debdutta Bhattacharya
January 2022, Journal of immunology research,
Hari Ram Choudhary, and Debaprasad Parai, and Girish Chandra Dash, and Annalisha Peter, and Subrat Kumar Sahoo, and Matrujyoti Pattnaik, and Usha Kiran Rout, and Rashmi Ranjan Nanda, and Sanghamitra Pati, and Debdutta Bhattacharya
January 2021, Human antibodies,
Hari Ram Choudhary, and Debaprasad Parai, and Girish Chandra Dash, and Annalisha Peter, and Subrat Kumar Sahoo, and Matrujyoti Pattnaik, and Usha Kiran Rout, and Rashmi Ranjan Nanda, and Sanghamitra Pati, and Debdutta Bhattacharya
February 2004, Biochemical and biophysical research communications,
Hari Ram Choudhary, and Debaprasad Parai, and Girish Chandra Dash, and Annalisha Peter, and Subrat Kumar Sahoo, and Matrujyoti Pattnaik, and Usha Kiran Rout, and Rashmi Ranjan Nanda, and Sanghamitra Pati, and Debdutta Bhattacharya
January 2021, Influenza and other respiratory viruses,
Hari Ram Choudhary, and Debaprasad Parai, and Girish Chandra Dash, and Annalisha Peter, and Subrat Kumar Sahoo, and Matrujyoti Pattnaik, and Usha Kiran Rout, and Rashmi Ranjan Nanda, and Sanghamitra Pati, and Debdutta Bhattacharya
January 2023, Infection and drug resistance,
Hari Ram Choudhary, and Debaprasad Parai, and Girish Chandra Dash, and Annalisha Peter, and Subrat Kumar Sahoo, and Matrujyoti Pattnaik, and Usha Kiran Rout, and Rashmi Ranjan Nanda, and Sanghamitra Pati, and Debdutta Bhattacharya
March 2022, Clinical laboratory,
Hari Ram Choudhary, and Debaprasad Parai, and Girish Chandra Dash, and Annalisha Peter, and Subrat Kumar Sahoo, and Matrujyoti Pattnaik, and Usha Kiran Rout, and Rashmi Ranjan Nanda, and Sanghamitra Pati, and Debdutta Bhattacharya
December 2021, BMC microbiology,
Hari Ram Choudhary, and Debaprasad Parai, and Girish Chandra Dash, and Annalisha Peter, and Subrat Kumar Sahoo, and Matrujyoti Pattnaik, and Usha Kiran Rout, and Rashmi Ranjan Nanda, and Sanghamitra Pati, and Debdutta Bhattacharya
July 2021, Clinical chemistry,
Hari Ram Choudhary, and Debaprasad Parai, and Girish Chandra Dash, and Annalisha Peter, and Subrat Kumar Sahoo, and Matrujyoti Pattnaik, and Usha Kiran Rout, and Rashmi Ranjan Nanda, and Sanghamitra Pati, and Debdutta Bhattacharya
August 2022, EJIFCC,
Hari Ram Choudhary, and Debaprasad Parai, and Girish Chandra Dash, and Annalisha Peter, and Subrat Kumar Sahoo, and Matrujyoti Pattnaik, and Usha Kiran Rout, and Rashmi Ranjan Nanda, and Sanghamitra Pati, and Debdutta Bhattacharya
March 2022, Vaccines,
Copied contents to your clipboard!